Core Insights - Emcure Pharmaceuticals is leveraging social media influencers and celebrities to promote its semaglutide brand, Poviztra, aiming to establish a strong presence in the weight-loss market [1][2][4] - The marketing strategy for GLP-1 drugs is evolving, moving beyond traditional doctor-focused approaches to include broader consumer engagement, similar to trends seen in Western markets [2][10] Company Strategy - Emcure launched Poviztra in December 2023 in partnership with Novo Nordisk, and is implementing a campaign called "Winning Over Obesity" featuring celebrities and influencer-doctors to raise awareness about obesity [1][4] - The company is focusing on educating both consumers and healthcare professionals about the benefits and safety of semaglutide, addressing misinformation prevalent on social media [5][6] Market Position - Poviztra is positioned as a competitive offering in the Indian market, with a pricing structure starting at approximately ₹2,200 per week, or ₹8,790 per month, across various strengths [7] - As the generic market for semaglutide opens next month, Emcure is expected to maintain competitive pricing while expanding awareness and access to its product [8] Financial Performance - Emcure reported a profit after tax of ₹231 crore in Q3FY26, reflecting a 48.2% year-on-year increase, with revenue rising 20.4% to ₹2,363 crore, driven by strong domestic and international performance [13][14] - The domestic business grew by 15.4%, particularly in chronic therapy segments, while international operations saw a 24.5% growth, indicating robust demand across all markets [14]